COHBAR INC (CWBR) Stock Price & Overview

NASDAQ:CWBR • US19249J3077

Current stock price

0.761 USD
-0.14 (-15.44%)
At close:
0.7345 USD
-0.03 (-3.48%)
After Hours:

The current stock price of CWBR is 0.761 USD. Today CWBR is down by -15.44%. In the past month the price decreased by -62.33%. In the past year, price decreased by -56.01%.

CWBR Key Statistics

52-Week Range0.65 - 6.9
Current CWBR stock price positioned within its 52-week range.
1-Month Range0.65 - 1.93
Current CWBR stock price positioned within its 1-month range.
Market Cap
2.215M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-4.36
Dividend Yield
N/A

CWBR Stock Performance

Today
-15.44%
1 Week
-15.44%
1 Month
-62.33%
3 Months
-71.82%
Longer-term
6 Months -73.39%
1 Year -56.01%
2 Years -94.82%
3 Years -98.12%
5 Years -99.38%
10 Years N/A

CWBR Stock Chart

COHBAR INC / CWBR Daily stock chart

CWBR Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to CWBR. When comparing the yearly performance of all stocks, CWBR is a bad performer in the overall market: 96.03% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CWBR Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CWBR. While CWBR seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CWBR Earnings

Next Earnings DateMar 7, 2024
Last Earnings DateNov 14, 2023
PeriodQ2 / 2023
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

CWBR Forecast & Estimates

6 analysts have analysed CWBR and the average price target is 18.36 USD. This implies a price increase of 2312.61% is expected in the next year compared to the current price of 0.761.


Analysts
Analysts43.33
Price Target18.36 (2312.61%)
EPS Next Y-3.7%
Revenue Next YearN/A

CWBR Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

CWBR Financial Highlights

Over the last trailing twelve months CWBR reported a non-GAAP Earnings per Share(EPS) of -4.36. The EPS increased by 8.02% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-12.69M
Industry RankSector Rank
PM (TTM) N/A
ROA -101.44%
ROE -133.58%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-58.51%
Sales Q2Q%N/A
EPS 1Y (TTM)8.02%
Revenue 1Y (TTM)N/A

CWBR Ownership

Ownership
Inst Owners6.24%
Shares2.91M
Float2.47M
Ins Owners238.68%
Short Float %N/A
Short RatioN/A

About CWBR

Company Profile

CWBR logo image CohBar, Inc. is a clinical stage biotechnology company, which engages in the research and development of mitochondria-based therapeutics targeting chronic and age-related diseases. The company is headquartered in Menlo Park, California and currently employs 9 full-time employees. The company went IPO on 2015-01-06. The firm is focused on developing therapeutics targeting chronic and age-related diseases. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing and optimizing novel analogs of these natural mitochondrial derived peptides (MDPs) and developing and conducting screens to identify and characterize the activities of these are referred to as its technology platform. Its advanced clinical candidate, CB4211, is a therapeutic for the treatment of nonalcoholic steatohepatitis and obesity. CB4211 demonstrated positive effects on reducing biomarkers of liver injury and improving metabolic homeostasis in a Phase 1a/1b clinical study in obese subjects with nonalcoholic fatty liver disease. CB4211 is a novel and improved analog of MOTS-c, a naturally occurring MDP. CB5138 Analogs are therapeutics that have demonstrated anti-fibrotic properties in a variety of preclinical models.

Company Info

IPO: 2015-01-06

COHBAR INC

1455 Adams Drive, Suite 2050

Menlo Park CALIFORNIA 94025 US

CEO: Steven Engle

Employees: 9

CWBR Company Website

Phone: 16504467888

COHBAR INC / CWBR FAQ

What does CWBR do?

CohBar, Inc. is a clinical stage biotechnology company, which engages in the research and development of mitochondria-based therapeutics targeting chronic and age-related diseases. The company is headquartered in Menlo Park, California and currently employs 9 full-time employees. The company went IPO on 2015-01-06. The firm is focused on developing therapeutics targeting chronic and age-related diseases. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing and optimizing novel analogs of these natural mitochondrial derived peptides (MDPs) and developing and conducting screens to identify and characterize the activities of these are referred to as its technology platform. Its advanced clinical candidate, CB4211, is a therapeutic for the treatment of nonalcoholic steatohepatitis and obesity. CB4211 demonstrated positive effects on reducing biomarkers of liver injury and improving metabolic homeostasis in a Phase 1a/1b clinical study in obese subjects with nonalcoholic fatty liver disease. CB4211 is a novel and improved analog of MOTS-c, a naturally occurring MDP. CB5138 Analogs are therapeutics that have demonstrated anti-fibrotic properties in a variety of preclinical models.


Can you provide the latest stock price for COHBAR INC?

The current stock price of CWBR is 0.761 USD. The price decreased by -15.44% in the last trading session.


Does COHBAR INC pay dividends?

CWBR does not pay a dividend.


What is the ChartMill technical and fundamental rating of CWBR stock?

CWBR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


How is the valuation of COHBAR INC (CWBR) based on its PE ratio?

COHBAR INC (CWBR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.36).


What is the next earnings date for CWBR stock?

COHBAR INC (CWBR) will report earnings on 2024-03-07, after the market close.


Who owns COHBAR INC?

You can find the ownership structure of COHBAR INC (CWBR) on the Ownership tab.